Healthcare Services

Fatty Acid Oxidation Disorders (FAODs) Market Size Outlook and Demand Growth Across 2026–2030

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Fatty Acid Oxidation Disorders (FAODs) Market During The Forecast Period 2026–2030?

The market for fatty acid oxidation disorders (faods) has seen robust growth in recent years. It is anticipated to grow from $10.23 billion in 2025 to $11.01 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.6%. The expansion observed in the past can be credited to the implementation of neonatal screening initiatives, an increased diagnosis of inherited metabolic disorders, enhanced clinical awareness, the expansion of hospital-based metabolic clinics, and the availability of supportive drug therapies.

The market size for fatty acid oxidation disorders (FAODs) is projected to experience robust growth in the coming years. It is anticipated to reach $14.69 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.5%. This expansion during the forecast period is driven by advancements in enzyme replacement therapies, the increasing scope of genetic research, the development of personalized nutrition plans, improved reimbursement policies for rare diseases, and heightened government support for early screening initiatives. Noteworthy trends over this period encompass the rising implementation of newborn screening programs, an increased focus on the early diagnosis of metabolic disorders, the expanding utilization of nutritional and dietary management techniques, greater awareness of rare disease treatments, and enhanced access to therapies for metabolic disorders.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21964&type=smp

Which Major Factors Are Driving The Expansion Of The Fatty Acid Oxidation Disorders (FAODs) Market?

The fatty acid oxidation disorders (FAODs) market is projected to expand due to the increasing demand for gene therapy. Gene therapy is a medical approach focused on altering or substituting faulty genes to treat or avert illnesses. The heightened interest in gene therapy stems from its potential to address genetic disorders, cancer, and rare diseases by targeting their root genetic causes, consequently attracting considerable investments and fostering progress in biotechnology. For fatty acid oxidation disorders, gene therapy strives to rectify metabolic deficiencies by delivering functional genes, thereby restoring enzymatic activity, boosting energy production, and preventing disease complications. As an illustration, in 2024, the American Society of Gene & Cell Therapy (ASGCT), a US-based, nonprofit, professional medical and scientific organization, reported that the global pipeline of gene, cell, and RNA therapies rose from 3,483 in Q4 2022 to 3,951 in Q4 2023, reaching 4,238 in Q4 2024. Consequently, the escalating demand for gene therapy is driving the growth of the fatty acid oxidation disorders (FAODs) market.

What Market Segments Are Evaluated Within The Fatty Acid Oxidation Disorders (FAODs) Market?

The fatty acid oxidation disorders (faods) market covered in this report is segmented –

1) By Type: Long Chain, Short Chain

2) By Drug Type: Levocarnitine, Dextrose, Riboflavin, Other Drug Types

3) By Route of Administration: Oral, Intravenous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Stores

5) By End User: Hospitals, Clinics, Pharmaceutical Companies

Subsegments:

1) By Long Chain: Very Long-Chain Acyl-CoA Dehydrogenase Deficiency (VLCAD), Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency (LCHAD), Trifunctional Protein Deficiency (TFP), Carnitine Palmitoyltransferase II Deficiency (CPT II)

2) By Short Chain: Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD), Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD), Carnitine Uptake Defect (CUD)

What Industry Trends Are Redefining The Fatty Acid Oxidation Disorders (FAODs) Market?

Leading companies engaged in the fatty acid oxidation disorders (FAODs) market are prioritizing the development of novel solutions, including peroxisome proliferator-activated receptor delta (PPARd) agonists, to improve metabolic control and patient outcomes for those with FAODs. A PPARd agonist is a compound that activates the PPARd receptor, which is crucial for regulating lipid metabolism, inflammation, and energy balance, potentially providing therapeutic benefits for metabolic and cardiovascular ailments. For example, in January 2023, Reneo Pharmaceuticals Inc., a clinical-stage pharmaceutical company based in the US, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for its experimental drug, Mavodelpar (REN001). This drug targets long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, a genotype associated with long-chain fatty acid oxidation disorder (LC-FAOD). Through PPARd activation, mavodelpar intends to enhance mitochondrial function, boost energy metabolism, and alleviate symptoms linked to LC-FAOD.

Who Are The Top Market Participants Influencing The Fatty Acid Oxidation Disorders (FAODs) Market?

Major companies operating in the fatty acid oxidation disorders (faods) market are Takeda Pharmaceutical Company Limited, Ultragenyx Pharmaceutical Inc, Sanofi SA, Novo Nordisk A S, Pfizer Inc, Merck & Co Inc, AstraZeneca PLC, Amgen Inc, AbbVie Inc, BioMarin Pharmaceutical Inc, PTC Therapeutics Inc, Horizon Therapeutics PLC, Recordati Rare Diseases SpA, Orphazyme A S, Mitsubishi Tanabe Pharma Corporation, Alexion Pharmaceuticals Inc (AstraZeneca Rare Disease), REGENXBIO Inc, Avrobio Inc, Homology Medicines Inc, Abeona Therapeutics Inc

Read the full fatty acid oxidation disorders (faods) market report here:

https://www.thebusinessresearchcompany.com/report/fatty-acid-oxidation-disorders-faods-global-market-report

Which Region Currently Holds The Largest Share Of The Fatty Acid Oxidation Disorders (FAODs) Market?

Asia-Pacific was the largest region in the fatty acid oxidation disorders (FAODs) market in 2025. The regions covered in the fatty acid oxidation disorders (faods) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Fatty Acid Oxidation Disorders (FAODs) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21964&type=smp

Browse Through More Reports Similar to the Global Fatty Acid Oxidation Disorders (FAODs) Market 2026, By The Business Research Company

Tall Oil Fatty Acid Global Market Report

https://www.thebusinessresearchcompany.com/report/tall-oil-fatty-acid-global-market-report

Fats And Oils Global Market Report

https://www.thebusinessresearchcompany.com/report/fats-and-oils-global-market-report

Palm Kernel Fatty Acids Global Market Report

https://www.thebusinessresearchcompany.com/report/palm-kernel-fatty-acids-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795